Business Context and Reporting Period
Company: Tempest Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 24, 2025
Reporting Period: Event date April 24, 2025; Signed April 28, 2025
Business Context: The Company is a Delaware corporation with its principal executive offices in Brisbane, California. Its common stock trades on The Nasdaq Stock Market LLC under the symbol "TPST."
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Regulatory Compliance Status: On April 24, 2025, the Company received formal notification from The Nasdaq Stock Market LLC confirming it has regained compliance with Nasdaq Listing Rule 5550(a)(2). This rule requires listed companies to maintain a minimum bid price of at least $1.00 per share.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the resolution of a prior non-compliance issue regarding the minimum bid price requirement.
Risks and Contingencies: The filing does not disclose new risks, contingencies, or unusual items beyond the context of the listing compliance event.
Guidance: No forward-looking financial guidance or operational outlook is provided in this document.
Key Facts for Investor Verification
- Verify the current trading price of TPST to ensure continued compliance with the $1.00 minimum bid price requirement.
- Confirm the specific mechanism used to regain compliance (e.g., reverse stock split, organic price appreciation) by reviewing prior filings or press releases.
- Check for any subsequent communications from Nasdaq regarding the duration of the compliance period.